Deutsche Bank lowered the firm’s price target on Praxis Precision (PRAX) to $420 from $444 and keeps a Buy rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRAX:
- Praxis Therapeutics: Advancing Late-Stage Neurology Pipeline and De-Risked Ulixacaltamide NDA Support Unchanged $554 Buy Target
- Praxis Precision reports Q1 EPS ($3.20), consensus ($3.68)
- Praxis Precision price target raised to $437 from $412 at Deutsche Bank
- Praxis Precision NDA for Ulixacaltamide in Essential Tremor
- Praxis Precision announces FDA acceptance of ulixacaltamide NDA